Med Spa Valuation and M&A Multiples Report 2026

Med Spa Valuation and M&A Multiples Report 2026: Benchmarks by Size and Model

Med spa valuation in 2026: about 3x to 6x EBITDA for spas under $4M of revenue, 5x to 8x at $4M to $20M and 7x to 12x above $20M, per AmSpa’s May 2026 M&A review.

Med spa valuation and M&A multiples report 2026 cover graphic
Med Spa Valuation and M&A Multiples Report 2026, CT Acquisitions, last reviewed November 2026

Key takeaways

  • Size sets the band: med spas under $4M of revenue traded at 3x to 6x EBITDA in 2025, and regional platforms above $20M at 7x to 12x, per AmSpa and Xite (May 15, 2026).
  • Quality sets the spot inside the band: premium assets command multiples 30% to 100% higher than undifferentiated peers, per the Skytale Group and Guidepoint Qsight report (December 2025).
  • Skytale’s investor screen: annual EBITDA above $1 million, gross profit above 65%, adjusted EBITDA margin above 20% and 50% retention of new patients.
  • Most deals pay about 60% cash at close and 40% rollover equity, rising to 80% cash and 20% rollover, per AmSpa and Xite.
  • No Q3 2026 med spa deal disclosed a price: CT’s Q3 2026 deal file counted 19 transactions and 0 priced, and PitchBook reported on October 14, 2026 that LaserAway’s sale process is no longer active.

What is a med spa worth in 2026?

A med spa is worth its normalized earnings times a market multiple. The three named sources that publish bands agree on the shape: 3x to 6x EBITDA for small spas, 5x to 8x for mid-size groups and 7x to 12x for regional platforms. Small owner-run spas listed for sale ask about 2.92x SDE. Only scaled national brands reach double digits.

Size or segmentEarnings basisMultipleSource and date
Revenue under $4M (single site, small)EBITDA3x to 6xAmSpa / Xite, May 15, 2026
Revenue $4M to $20M (multi-site)EBITDA5x to 8xAmSpa / Xite, May 15, 2026
Revenue over $20M (regional platform)EBITDA7x to 12xAmSpa / Xite, May 15, 2026
Revenue under $5MEBITDA3x to 6xScope Research, January 23, 2025 (updated May 5)
Revenue $5M to $20MEBITDA5x to 8xScope Research, 2025
Revenue over $20MEBITDA7x to 12xScope Research, 2025
High-growth national platformsEBITDA10x to 20x (a handful of precedent deals)Scope Research, 2025
Owner-run listings for sale (164 US listings, asking)SDE2.92x median askMain Street Index, October 5, 2026
LaserAway sale talk (219 clinics)EBITDA, derivedabout 13.3x ($2 billion over about $150 million)Reuters via Private Equity Wire, June 2026; process ended per PitchBook, October 14, 2026
Range chart of med spa EBITDA multiples by revenue band from AmSpa and Scope Research, 3x to 6x up to 7x to 12x
Med spa EBITDA multiples by revenue band: AmSpa / Xite (May 15, 2026) and Scope Research (2025) agree on 3x to 6x, 5x to 8x and 7x to 12x.

Two cautions on the table. The AmSpa and Scope bands are set by revenue, not by EBITDA, so a $3M spa with a 25% margin and one with a 10% margin sit in the same band at very different values. The Main Street Index figure is an asking multiple on 164 listings with a median SDE of $192K, not a closing price; listings that named a medical director asked 2.85x against 2.96x without one.

The LaserAway number is derived, not reported. Reuters said on June 4, 2026 that a sale could value the chain above $2 billion, the roughly $150 million EBITDA figure came from trade write-ups, and PitchBook reported on October 14, 2026 that the process is no longer active. Treat 13.3x as a ceiling for a 219-clinic national brand, not a comp for a single spa.

Is a med spa valued on SDE or EBITDA?

Owner-run single-site spas are priced on seller’s discretionary earnings (SDE), which adds back one owner’s full pay. Groups with a manager and several injectors are priced on adjusted EBITDA, after a market salary for every provider, owner included. The same spa can show $550,000 of SDE and $380,000 of adjusted EBITDA, so always name the basis before quoting a multiple.

ItemSDEAdjusted EBITDA
Who uses itIndividual and SBA-financed buyers of owner-run spasPE-backed platforms, independent sponsors, strategic groups
Owner’s payAdded back in fullReplaced with market pay for the injector and manager roles
Medical director feeKept as a costKept at a market rate, even if the owner is the director
Rent on a building the owner holdsAdjusted to marketAdjusted to market
Typical published multiple2.92x median asking (Main Street Index, 2026)3x to 12x by size (AmSpa / Xite, 2026)

Do not blend the two. A practice at the boundary should be modeled twice and negotiated on the stronger basis; a seller who quotes a 5x EBITDA multiple against an SDE figure overstates the price by the owner’s pay times the multiple, and a buyer’s quality of earnings review will find it. Our quality of earnings guide shows what that review tests.

How do you calculate med spa valuation? A worked example

Normalize earnings, pick the basis, apply the band, then bridge to cash. The example below uses Zenoti’s CY2025 median revenue per med spa location of $1.86M and AmSpa’s revenue bands. It is illustrative arithmetic, not an appraisal: a single site lands at $1.14M to $2.28M, and a three-site group at $6.14M to $9.82M.

  1. Normalize. Start from net income, add back owner pay, interest, depreciation and amortization, and one-time or personal costs. That gives SDE.
  2. Pick the basis. For a platform buyer, subtract market pay for the work the owner does (lead injector, manager). That gives adjusted EBITDA.
  3. Apply the band. Use the revenue band from AmSpa and Xite, then move up or down with the drivers in the next section.
  4. Bridge to proceeds. Enterprise value minus debt, plus or minus the working capital adjustment, then split into cash at close and rollover equity.
Line (illustrative)Single-site spaThree-site group
Revenue$1,860,000 (Zenoti CY2025 median)$5,580,000 (three median sites)
Net income$260,000n/a
Add back owner salary$180,000n/a
Add back one-time and personal costs$50,000n/a
Add back interest, depreciation, amortization$60,000n/a
SDE$550,000n/a
Less market pay for the owner’s roles$170,000n/a
Adjusted EBITDA$380,000 (20.4% margin)$1,227,600 (22% margin)
AmSpa / Xite band3x to 6x (under $4M revenue)5x to 8x ($4M to $20M revenue)
Enterprise value range$1,140,000 to $2,280,000$6,138,000 to $9,820,800
Midpoint multiple and value4.5x = $1,710,0006.5x = $7,979,400
60% cash at close$1,026,000$4,787,640
40% rollover equity$684,000$3,191,760
Bar chart of illustrative med spa value ranges: single site 1.14M to 2.28M, three-site group 6.14M to 9.82M
Illustrative enterprise value ranges on AmSpa / Xite bands, using Zenoti’s CY2025 median revenue of $1.86M per location. Not an appraisal.

The single site clears Skytale’s 20% adjusted EBITDA margin line but sits far below its $1 million EBITDA mark for competitive valuations, which is why it lands in the 3x to 6x band. The three-site group crosses $1 million and enters the 5x to 8x band. Moving from the midpoint to the top of each band is worth $570,000 for the single site and $1,841,400 for the group, which is the money the drivers below decide.

What raises or lowers a med spa’s multiple?

Provider independence, recurring revenue, margin and clean compliance files move a med spa within its band. Skytale names clinician retention, membership penetration, geographic density and data quality as the drivers of its 30% to 100% premium, and it sets hard investor lines: EBITDA above $1 million, gross profit above 65% and adjusted EBITDA above 20%.

DriverBuyer thresholdEffect on valueSource
ScaleAnnual EBITDA above $1 millionBelow it, fewer competitive bidsSkytale / Qsight, Dec 2025
Gross profitAbove 65%, excluding direct laborBelow it, buyer questions pricing and product costSkytale / Qsight
Adjusted EBITDA marginAbove 20%; 20% to 30% seen as resilientThin margins pull toward the low end of the bandSkytale / Qsight
Patient retention50% of new patients, up to 80% of returning patientsHigher retention supports recurring-revenue creditSkytale / Qsight
Repeat-patient benchmark73% repeat patients is the industry averageBelow average reads as a transactional spaAmSpa 2024 report
Service mixAbout 60% injectables, rest across devices, skincare, weight lossA heavy medical weight loss mix “makes investors nervous”Skytale / Qsight
Site count3 to 8 or more sitesDraws the most competitive interestAmSpa / Xite, May 2026
Compliance filesMedical director, injector supervision and MSO documents in orderGaps cut price or stall diligence, mostly in CaliforniaAmSpa / Xite, May 2026
Sale processSeveral bidders, not one unsolicited offerA 126% gap between lowest and highest bid in one Bundy Group dermatology salePractical Dermatology, Sept 2025
Med spa treatment room used to compare med spa valuation by service mix

Owner dependence is the most common reason a small spa sits at 3x rather than 6x. AmSpa and Xite say owner dependence and operational concentration push smaller spas to the low end, and Skytale adds that patients should be loyal to the brand, not to one provider. Our note on how owner dependency affects valuation shows how buyers test it.

Which treatments are buyers paying for?

Neurotoxins are the growth line buyers pay for: US neurotoxin patient spend rose 8% to $6.4 billion in 2024 while the non-surgical market grew 5% to $20.5 billion, per Qsight. Body contouring fell 22% and laser hair removal 9%, so a device-heavy spa carries more demand risk than an injector-led one.

Category2024 US patient spendChange vs 2023Source
All non-surgical aesthetics$20.5 billion+5%Skytale / Qsight, Dec 2025
Neurotoxins$6.4 billion+8%Skytale / Qsight
Dermal fillers$3.8 billion-3%Skytale / Qsight
Hyaluronic acid fillers$3.0 billion-4%Skytale / Qsight
Biostimulatory fillers$787 million+4%Skytale / Qsight
Energy-based devices$3.6 billion-5%Skytale / Qsight
Skin tighteningn/a+6%Skytale / Qsight
Laser hair removaln/a-9%Skytale / Qsight
Body contouringn/a-22%Skytale / Qsight
Medical weight loss (mostly compounded GLP-1)11% of spend+55% (after +235% in 2023)Skytale / Qsight
Bar chart of 2024 US aesthetics spend growth by category, neurotoxins up 8 percent and body contouring down 22 percent
Change in 2024 US patient spend by treatment category, from the Skytale Group and Guidepoint Qsight report (December 2025).

Supplier results through Q3 2026 point the same way. AbbVie reported US Botox Cosmetic net revenue of $388M, up 2.4%, and US Juvederm at $90M, down 6.3%, for Q3 2026, and Galderma reported neuromodulator sales up 16.9% at constant currency for the first nine months of 2026. A spa whose revenue leans on HA filler or one device is selling into the weakest lines.

Who is buying med spas in 2026, and who owns the big platforms?

Private equity platforms are the main buyers, but they own little of the market: AmSpa’s 2024 report puts PE ownership at 3% of med spas and single-location spas at 81%. The table lists each platform’s sponsor with the dated release behind it, so an owner can check who is behind an offer before taking a call.

PlatformSponsorDated eventSource
Ideal ImageL Catterton (majority); TPG Growth (minority)L Catterton bought parent Steiner Leisure in 2015; TPG Growth invested May 11, 2021TPG release, Business Wire
Milan Laser Hair RemovalLeonard Green & Partners; Sixth Street and Wildcat Capital (growth)LGP since 2019; Sixth Street and Wildcat invested February 22, 2023, LGP and co-founders keep majorityLeonard Green release
LaserAwayAres Management; Seidler Equity PartnersSeidler since 2018; Ares invested October 21, 2021; sale explored June 2026, process ended per PitchBook October 14, 2026LaserAway release, Business Wire
SkinSpiritKKR (minority, Health Care Strategic Growth Fund II); GreyLion (minority since 2018)KKR investment announced October 20, 2022SkinSpirit release, Business Wire
VIO Med Spa (franchisor)Freeman Spogli (majority)Announced September 16, 2024VIO release, PR Newswire
Advanced MedAesthetic Partners (Avelure, Ever/Body)Leon Capital GroupAcquired Ever/Body, December 2025 (PitchBook data)Edgepoint flash report, March 2026
Alpha Aesthetics PartnersThurston Group37 locations; $93 million Manulife-led debt; sale under consideration, October 14, 2026PitchBook via Yahoo Finance
MD EstheticsNew Harbor CapitalFour add-ons took it from 12 to 35 locations, September 16, 2026PR Newswire
Aviva AestheticsDuneGlass CapitalMuse Med Spa, its 11th partnership of 2026, September 16, 2026Aviva newsroom
Olympus Cosmetic GroupVSS Capital PartnersGallaher Plastic Surgery & Med Spa, September 9, 2026PR Newswire
Elase Medical SpasImperial CapitalDerma Health, Phoenix metro, July 2026AZ Big Media, July 31, 2026
Cosmetic Physician PartnersNone stated (practitioner-owned)About $35 million distribution to practitioner-owners, July 22, 2026PR Newswire
Timeline of private equity entries into med spa platforms from 2015 to 2026, from L Catterton to the LaserAway sale talk
When current sponsors entered the largest med spa platforms, each date from the company or sponsor release; LaserAway sale process ended per PitchBook, October 14, 2026.

CT’s Q3 2026 deal file, compiled from press releases and company newsrooms for our Medspa Market Report, counted 16 announced entries covering 19 transactions between July 1 and September 30, 2026, and 0 disclosed a price or multiple. That is why every multiple on this page comes from an advisor benchmark rather than a deal comp. PitchBook expects as many as 25 med spa platforms to come to market in 2027 and 2028, which would add the first scaled comps.

What deal structure should a med spa owner expect?

Expect part of the price in cash and part in the buyer’s equity. AmSpa and Xite report about 60% cash at close and 40% rollover equity in most 2025 deals, rising to 80% cash and 20% rollover, with holdbacks and earnouts common where provider transition matters. Compare offers on cash at close, not headline value.

TermTypical range or exampleSource
Cash at closeAbout 60%, up to 80%AmSpa / Xite, May 15, 2026
Rollover equityAbout 40%, down to 20%AmSpa / Xite, May 15, 2026
Rollover exampleSell 70%, roll 30% into the platformAmSpa / Xite, August 14, 2026
Seller note example80% at close, 20% as a seller noteAmSpa / Xite, August 14, 2026
Holdbacks and earnoutsCommon where future performance or provider transition is keyAmSpa / Xite, May 15, 2026

Rollover equity pays only when the platform sells, so its value depends on the sponsor’s exit; our founder rollover equity benchmarks cover the terms to negotiate. Earnouts tied to EBITDA or patient retention shift risk back to the seller, and the earnout benchmarks by deal size show common lengths and triggers.

How do CPOM and state laws affect med spa valuation?

Corporate practice of medicine (CPOM) rules decide who may own the medical side of a med spa, so they decide which buyers can bid and how the deal is built. California SB 351 took effect January 1, 2026, Oregon SB 951 applies to new MSO deals from January 1, 2026, and a federal bill introduced September 16, 2026 would extend similar limits nationally.

RuleKey datesWhat it doesEffect on a sale
California SB 351Signed October 6, 2025; effective January 1, 2026Bars PE and management firms from interfering with clinical judgment; voids certain MSO contract termsCalifornia MSO and friendly-PC agreements get re-reviewed in diligence
California AB 1415Signed October 11, 2025PE groups, hedge funds and MSOs must give at least 90 days’ notice of covered deals to the Office of Health Care AffordabilityAdds at least 90 days to the timeline for covered deals
Oregon SB 951Signed June 9, 2025; new and sold structures from January 1, 2026; older structures by January 1, 2029Bans MSO control of medical groups; limits noncompetes; private right of actionA sale after June 9, 2025 triggers the 2026 rules, not the 2029 grace period
Texas HB 3749Signed June 20, 2025; effective September 1, 2025Elective IV therapy needs a prior evaluation and an order from a physician or delegated PA or NPIV revenue without those records is a diligence finding
FDA 503B bulks proposalFederal Register, May 1, 2026Proposes removing semaglutide, tirzepatide and liraglutide from the 503B bulks listCompounded GLP-1 revenue is treated as at-risk
Federal practice-ownership billIntroduced September 16, 2026; in committeeWould require majority ownership by licensed professionals and limit MSO controlA watch item for MSO-based buyers if it moves

The dermatology side of the market faces the same CPOM rules with insurance billing on top; the dermatology M&A multiples report compares the two, and the healthcare services multiples report places both in the wider sector.

Should you sell your med spa now or fix it first?

Sell now if the spa already meets the buyer thresholds; fix first if one gap would move it a full band. The decision table uses the Skytale and AmSpa lines above. If your situation matches a row, the right-hand column is the next step, and the time it takes is the cost of waiting.

If your situation isThenWhy (source)
If EBITDA is above $1 million, margin above 20% and no provider carries the bookRun a competitive sale now with several biddersMeets Skytale’s investor lines; bids in one Bundy Group sale ranged 126% apart
If you run 3 to 8 sites in Florida, Texas or CaliforniaApproach platforms and new sponsors togetherAmSpa / Xite name these as the most active states and site counts
If you inject most of the patients yourselfHire and ramp an associate injector before going to marketOwner dependence pushes small spas to the low end of 3x to 6x (AmSpa / Xite)
If medical weight loss is a larger share of revenue than the 11% national spend shareShow the rest of the mix stands alone; document prescribing and sourcingSkytale: a heavy weight loss mix makes investors nervous; FDA 503B proposal, May 2026
If you operate in California or Oregon through an MSOHave counsel review the MSO and PC agreements before an LOISB 351 (CA) and SB 951 (OR) apply to 2026 deals
If repeat patients are below the 73% averageBuild memberships and treatment plans firstAmSpa 2024 benchmark; Skytale retention lines of 50% and 80%
Flowchart for med spa owners: EBITDA above 1 million, owner dependence, weight loss mix and state rules lead to sell now or fix first
Sell now or fix first: the thresholds come from Skytale Group (EBITDA above $1 million, margin above 20%) and AmSpa / Xite (owner dependence, 3 to 8 sites).

The step-by-step sale process (data room, confidential outreach, comparing letters of intent) is in our guide on how to sell a med spa, and the advisor side is on our M&A advisor for med spas page.

Thinking about selling your med spa? CT Acquisitions helps owners of founder-owned businesses make the most of their exit through a confidential sale, recapitalization or exit planning, with a 500+ buyer network. We work for owners on the sell side. Our fee is success only: nothing upfront, and you pay nothing unless the business sells.

Book a confidential call to see where your EBITDA, provider mix and state rules place you against the bands above.

How we compiled this

We compiled this page in November 2026 from 30 dated documents: AmSpa industry reports and articles, the Skytale Group and Guidepoint Qsight report, Scope Research, Zenoti benchmark data, sponsor and company press releases, AbbVie and Galderma results, statute pages and law firm alerts. Multiples come only from named advisor or data sources, and the deal record comes from CT’s Q3 2026 Medspa Market Report file. We excluded forum posts and any multiple we could only see in a search snippet. Nothing here is an appraisal of any business.

Research binders showing the method behind med spa valuation figures

Frequently asked questions

What is the EBITDA multiple for a med spa?

Med spas sold for about 3x to 6x EBITDA under $4M of revenue, 5x to 8x at $4M to $20M and 7x to 12x above $20M in 2025, per AmSpa and Xite (May 15, 2026). Scope Research reports the same bands and 10x to 20x for a handful of high-growth national platforms.

How much money does a med spa owner make?

The average US med spa brought in $1,398,833 of revenue in 2023, per AmSpa’s 2024 report, and Zenoti puts the CY2025 median at $1.86M per location. Skytale says well-run spas earn adjusted EBITDA margins of 20% to 30%, so owner earnings before their own pay often run several hundred thousand dollars.

Is private equity buying med spas?

Yes, but slowly. AmSpa’s 2024 report puts private equity ownership at 3% of med spas, and Skytale expects about 10% total consolidation over the next 4 to 5 years. Active 2026 buyers include MD Esthetics (New Harbor Capital), Aviva Aesthetics (DuneGlass Capital) and Olympus Cosmetic Group (VSS Capital Partners).

How profitable are medical spas?

Skytale and Guidepoint Qsight say consistent margins of 20% to 30% are possible, and private equity buyers look for gross profit above 65% and adjusted EBITDA above 20%. AmSpa’s 2024 report shows $527 average spend per visit and 73% repeat patients, the two numbers that drive that margin.

Who owns a med spa?

Most med spas are owner-run: AmSpa’s 2024 report counts 81% as single-location businesses and 3% as private equity owned. In states with corporate practice of medicine rules, such as California, the medical side must be owned by a licensed professional, and investors hold the business side through a management services organization.

Did LaserAway sell?

No sale had been announced as of November 2026. Reuters reported on June 4, 2026 that Ares-backed LaserAway was exploring a sale that could value it above $2 billion, and PitchBook reported on October 14, 2026 that the process is no longer active.

Sources

All sources accessed November 2026.

Observed ranges reported by third-party sources. Not an appraisal, not investment, legal, tax or financial advice.

Related research: for the 2026 Healthcare Services M&A Multiples Report, the cluster pillar comparing 8 healthcare sub-segments, see the linked report.

Related research: for the 2026 Dermatology M&A Multiples Report, adjacent sibling with distinct axis (derm insurance + medical + cosmetic mix; med spa 100% cash-pay), see the linked report.

Related research: for the 2026 Optometry Practice M&A Multiples Report, sibling healthcare specialty spoke, see the linked report.

Related research: for the 2026 Physical Therapy Practice M&A Multiples Report, sibling healthcare specialty spoke, see the linked report.